Rio Olympics end with big TV ad spending tallies, but pharma marketers finish in middle of pack

Pharma companies finished in the middle of the pack of blockbuster TV advertisers during the Olympic Games in Rio. While total TV spending was a whopping $1.18 billion, pharma only contributed $45 million during the 17-day event, according to real time TV ad tracker

The top spending pharma brand was Novo Nordisk’s GLP-1 diabetes treatment Victoza at $9.2 million, followed by two Pfizer drugs, the pain medication Lyrica at $9.1 million and the anti-inflammatory Xeljanz at $5.7 million. That compares to top spending consumer brands such as Chrysler, which spent $25 million on one commercial along and $15.2 million on another, or Samsung, which spent $17.1 million on one ad and $12 million on another one.


Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.


Overall, 20 pharma brands and companies ran 293 TV ads during Olympic coverage, on channels including NBC primetime and cable outlets NBC Sports, CNBC, MSNBC and USA Network.

Merck, Mylan and Pfizer ran corporate or disease awareness commercials, while some of the other pharma brands airing ads included Bayer and Johnson & Johnson's anticoagulant Xarelto and Lundbeck and Takeda’s antidepressant Trintellix.

However, being a middle-of-the-road advertiser in these Games may not have been a bad move. Bloomberg reported that Olympic Games TV viewership was down 17% from the London Games in 2012, accounting for the first Summer Games’ decline in ratings since 2000.

- look up ads on iSpot
- read more on Bloomberg

Special Report: The top 10 advertisers in Big Pharma | The top 10 most-advertised prescription drug brands

Related Articles:
Going for emotion: Pharma takes a page from consumer marketers for Olympic ads
Celgene brings on Olympic swimmer to help Otezla lap psoriasis rivals
Pharma brings the heat in July as TV ad spending soars
Valeant, AstraZeneca played the Super Bowl ad game, but did they win?

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.